tradingkey.logo

Natera Inc

NTRA
230.630USD
+5.080+2.25%
終値 11/21, 16:00ET15分遅れの株価
31.35B時価総額
損失額直近12ヶ月PER

Natera Inc

230.630
+5.080+2.25%

詳細情報 Natera Inc 企業名

Natera, Inc. is a diagnostics company, which is focused on the development and commercialization of molecular testing services, applying its technology in the fields of women’s health, oncology and organ health. Its cell-free deoxyribonucleic acid (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell. The Company's product offerings include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening, Spectrum Preimplantation Genetics, Anora Miscarriage Test, Empower, and Prospera. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Company’s algorithms and bioinformatics in order to validate and launch tests based on the Company’s technology. Its NIPT screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother.

Natera Incの企業情報

企業コードNTRA
会社名Natera Inc
上場日Jul 02, 2015
最高経営責任者「CEO」Mr. Steven Leonard (Steve) Chapman
従業員数4424
証券種類Ordinary Share
決算期末Jul 02
本社所在地13011 Mccallen Pass
都市AUSTIN
証券取引所NASDAQ Global Select Consolidated
United States of America
郵便番号78753
電話番号16502499090
ウェブサイトhttps://www.natera.com/
企業コードNTRA
上場日Jul 02, 2015
最高経営責任者「CEO」Mr. Steven Leonard (Steve) Chapman

Natera Incの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Matthew Rabinowitz, Ph.D.
Dr. Matthew Rabinowitz, Ph.D.
Executive Chairman of the Board, Co-Founder
Executive Chairman of the Board, Co-Founder
2.28M
-1.72%
Mr. Roelof Frederick Botha
Mr. Roelof Frederick Botha
Lead Independent Director
Lead Independent Director
1.23M
+0.01%
Mr. Jonathan Sheena
Mr. Jonathan Sheena
Co-Founder, Director
Co-Founder, Director
305.25K
-1.00%
Mr. Daniel A Rabinowitz
Mr. Daniel A Rabinowitz
Secretary, Chief Legal Officer
Secretary, Chief Legal Officer
150.99K
-1.05%
Mr. John Fesko
Mr. John Fesko
President, Chief Business Officer
President, Chief Business Officer
86.09K
-2.32%
Herman Rosenman, CPA
Herman Rosenman, CPA
Independent Director
Independent Director
65.67K
+0.23%
Mr. Solomon Moshkevich
Mr. Solomon Moshkevich
President - Clinical Diagnostics
President - Clinical Diagnostics
37.71K
-7.37%
Dr. Monica Bertagnolli, M.D.
Dr. Monica Bertagnolli, M.D.
Independent Director
Independent Director
6.22K
+1.52%
Dr. Rowan E. Chapman, Ph.D.
Dr. Rowan E. Chapman, Ph.D.
Independent Director
Independent Director
3.18K
+4.20%
Mr. Steven Leonard (Steve) Chapman
Mr. Steven Leonard (Steve) Chapman
Chief Executive Officer, Director
Chief Executive Officer, Director
3.17K
-28.17%
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Matthew Rabinowitz, Ph.D.
Dr. Matthew Rabinowitz, Ph.D.
Executive Chairman of the Board, Co-Founder
Executive Chairman of the Board, Co-Founder
2.28M
-1.72%
Mr. Roelof Frederick Botha
Mr. Roelof Frederick Botha
Lead Independent Director
Lead Independent Director
1.23M
+0.01%
Mr. Jonathan Sheena
Mr. Jonathan Sheena
Co-Founder, Director
Co-Founder, Director
305.25K
-1.00%
Mr. Daniel A Rabinowitz
Mr. Daniel A Rabinowitz
Secretary, Chief Legal Officer
Secretary, Chief Legal Officer
150.99K
-1.05%
Mr. John Fesko
Mr. John Fesko
President, Chief Business Officer
President, Chief Business Officer
86.09K
-2.32%
Herman Rosenman, CPA
Herman Rosenman, CPA
Independent Director
Independent Director
65.67K
+0.23%

収益内訳

通貨: USD更新時刻: Mon, Oct 6
通貨: USD更新時刻: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
事業別USD
会社名
収益
比率
Insurance carriers
516.99M
94.58%
Laboratory and other partners
22.17M
4.06%
Patients
7.44M
1.36%
地域別USD
会社名
収益
比率
United States
537.80M
98.39%
Europe, Middle East, India, Africa
5.41M
0.99%
Asia Pacific and Other
1.82M
0.33%
Americas, excluding U.S
1.57M
0.29%
事業別
地域別
事業別USD
会社名
収益
比率
Insurance carriers
516.99M
94.58%
Laboratory and other partners
22.17M
4.06%
Patients
7.44M
1.36%

株主

更新時刻: Sun, Nov 16
更新時刻: Sun, Nov 16
株主統計
種類
株主統計
株主統計
比率
The Vanguard Group, Inc.
8.94%
T. Rowe Price Associates, Inc.
8.57%
JP Morgan Asset Management
7.02%
BlackRock Institutional Trust Company, N.A.
4.92%
Farallon Capital Management, L.L.C.
3.08%
他の
67.48%
株主統計
株主統計
比率
The Vanguard Group, Inc.
8.94%
T. Rowe Price Associates, Inc.
8.57%
JP Morgan Asset Management
7.02%
BlackRock Institutional Trust Company, N.A.
4.92%
Farallon Capital Management, L.L.C.
3.08%
他の
67.48%
種類
株主統計
比率
Investment Advisor
46.30%
Investment Advisor/Hedge Fund
27.01%
Hedge Fund
12.75%
Individual Investor
3.07%
Family Office
2.73%
Family Office
2.73%
Family Office
2.46%
Bank and Trust
1.98%
Research Firm
1.60%

機関投資家保有株

更新時刻: Wed, Oct 1
更新時刻: Wed, Oct 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q3
1200
128.93M
93.94%
-2.81M
2025Q2
1137
131.96M
96.64%
-402.16K
2025Q1
1129
133.60M
97.90%
+2.21M
2024Q4
1001
128.40M
95.17%
-537.76K
2024Q3
896
125.06M
100.75%
-6.81M
2024Q2
850
125.13M
101.89%
-7.92M
2024Q1
798
124.30M
101.71%
-6.12M
2023Q4
781
119.55M
99.60%
-13.66M
2023Q3
787
122.52M
102.97%
-5.30M
2023Q2
792
116.72M
102.40%
-10.10M
詳細を見る

株主動向

会社名
保有株式数
比率
変動額
変動率
日付
The Vanguard Group, Inc.
12.62M
9.2%
+279.77K
+2.27%
Jun 30, 2025
T. Rowe Price Associates, Inc.
12.07M
8.79%
+1.64M
+15.72%
Jun 30, 2025
JP Morgan Asset Management
8.92M
6.5%
+2.53M
+39.53%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
6.78M
4.94%
+101.02K
+1.51%
Jun 30, 2025
Farallon Capital Management, L.L.C.
4.82M
3.51%
+274.00K
+6.02%
Jun 30, 2025
State Street Investment Management (US)
3.32M
2.42%
-53.04K
-1.57%
Jun 30, 2025
Duquesne Family Office LLC
3.09M
2.25%
-317.14K
-9.32%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.55M
1.86%
+166.77K
+6.99%
Jun 30, 2025
Franklin Advisers, Inc.
1.93M
1.41%
+330.96K
+20.65%
Jun 30, 2025
Wellington Management Company, LLP
2.63M
1.92%
-426.00K
-13.92%
Jun 30, 2025
詳細を見る

関連ETF

更新時刻: Thu, Nov 6
更新時刻: Thu, Nov 6
銘柄名
比率
Franklin Genomic Advancements ETF
6.11%
Alger Weatherbie Enduring Growth ETF
5.61%
VanEck Biotech ETF
4.16%
Alger 35 ETF
4.03%
ARK Genomic Revolution ETF
3.94%
Global X Genomics & Biotechnology ETF
3.85%
First Trust Nasdaq Lux Digi Health Solutions ETF
3.83%
Invesco Dorsey Wright Healthcare Momentum ETF
3.38%
TrueShares Technology, AI & Deep Learning ETF
3.21%
First Trust NYSE Arca Biotechnology Index Fund
3.12%
詳細を見る
Franklin Genomic Advancements ETF
比率6.11%
Alger Weatherbie Enduring Growth ETF
比率5.61%
VanEck Biotech ETF
比率4.16%
Alger 35 ETF
比率4.03%
ARK Genomic Revolution ETF
比率3.94%
Global X Genomics & Biotechnology ETF
比率3.85%
First Trust Nasdaq Lux Digi Health Solutions ETF
比率3.83%
Invesco Dorsey Wright Healthcare Momentum ETF
比率3.38%
TrueShares Technology, AI & Deep Learning ETF
比率3.21%
First Trust NYSE Arca Biotechnology Index Fund
比率3.12%

配当金

過去5年間の配当金総支払額は 0.00 米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし

株式分割

日付
種類
比率
データなし
日付
種類
比率
データなし

よくある質問

Natera Incの上位5名の株主は誰ですか?

Natera Incの上位5名の株主は以下のとおりです。
The Vanguard Group, Inc.は12.62M株を保有しており、これは全体の9.20%に相当します。
T. Rowe Price Associates, Inc.は12.07M株を保有しており、これは全体の8.79%に相当します。
JP Morgan Asset Managementは8.92M株を保有しており、これは全体の6.50%に相当します。
BlackRock Institutional Trust Company, N.A.は6.78M株を保有しており、これは全体の4.94%に相当します。
Farallon Capital Management, L.L.C.は4.82M株を保有しており、これは全体の3.51%に相当します。

Natera Incの株主タイプ上位3種は何ですか?

Natera Incの株主タイプ上位3種は、
The Vanguard Group, Inc.
T. Rowe Price Associates, Inc.
JP Morgan Asset Management

Natera Inc(NTRA)の株式を保有している機関の数はいくつですか?

2025Q3時点で、Natera Incの株式を保有している機関は1200社あり、保有株式の総市場価値は約128.93Mで、全体の93.94%を占めています。2025Q2と比較して、機関の持ち株は-2.70%増加しています。

Natera Incの最大の収益源は何ですか?

FY2025Q2において、Insurance carriers部門がNatera Incにとって最大の収益を生み出しており、その金額は516.99Mで、全収益の94.58%を占めています。
KeyAI